MYOFORMIN Trademark

Trademark Overview


On Wednesday, March 19, 2025, a trademark application was filed for MYOFORMIN with the United States Patent and Trademark Office. The USPTO has given the MYOFORMIN trademark a serial number of 99092562. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, March 19, 2025. This trademark is owned by Emmyon, Inc.. The MYOFORMIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson’s disease, Alzheimer’s disease, rheumatoid arthritis, autoimmune disorders, Cushing’s syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; Pharmaceutical preparations for the prevention of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Park...
myoformin

General Information


Serial Number99092562
Word MarkMYOFORMIN
Filing DateWednesday, March 19, 2025
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateWednesday, March 19, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson’s disease, Alzheimer’s disease, rheumatoid arthritis, autoimmune disorders, Cushing’s syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; Pharmaceutical preparations for the prevention of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson’s disease, Alzheimer’s disease, rheumatoid arthritis, autoimmune disorders, Cushing’s syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, bariatric surgery, or conditions that accompany treatment with weight loss medications; or conditions or complications associated with any of the foregoing; Nutraceuticals for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson’s disease, Alzheimer’s disease, rheumatoid arthritis, autoimmune disorders, Cushing’s syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; Nutraceuticals for use as a dietary supplement for inhibiting muscle atrophy, inhibiting sarcopenia, inhibiting muscular weakness, inhibiting fatigue, inhibiting obesity, inhibiting diabetes, promoting muscle health, promoting muscular strength

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 19, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEmmyon, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRochester, MN 55902

Trademark Events


Event DateEvent Description
Wednesday, March 19, 2025NEW APPLICATION ENTERED
Wednesday, March 19, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 19, 2025APPLICATION FILING RECEIPT MAILED